Trial Profile
Reduction of peripheral blood T cells producing IFN-gamma and IL-17 after therapy with abatacept for rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 18 Dec 2015 New trial record